TISSUE REGENERATION THERAPEUTICS INC has a total of 20 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Brazil. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are ANAEROPHARMA SCIENCE INC, ANTIGEN EXPRESS INC and NATIONWIDE CHILDRENS HOSPITAL.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Brazil | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Israel | 2 | |
#6 | Republic of Korea | 2 | |
#7 | Australia | 1 | |
#8 | Canada | 1 | |
#9 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Surface technology and coating | |
#6 | Machines | |
#7 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides | |
#5 | Unspecified technologies | |
#6 | Coating metallic material | |
#7 | Object sterilising | |
#8 | Analysing materials | |
#9 | Specific use of cosmetics | |
#10 | Fermentation |
# | Name | Total Patents |
---|---|---|
#1 | Davies John E | 10 |
#2 | Ennis Jane Elizabeth | 7 |
#3 | Davies John Edward | 7 |
#4 | Turner Jeffrey Donald | 7 |
#5 | Lickorish Antony D S | 3 |
#6 | Sarugaser Rahul | 3 |
#7 | Baksh Dolores | 3 |
#8 | Hosseini Morris | 3 |
#9 | Braid Lorena Ruth | 2 |
#10 | Estrada Vallejo Catalina | 2 |
Publication | Filing date | Title |
---|---|---|
WO2021022377A1 | Perivascular lysates and uses thereof | |
US2019134101A1 | Genetically modified human umbilical cord perivascular cells for wound healing | |
US2019125804A1 | Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc) | |
BR112012006980A2 | Method for forming a calcium phosphate coating, material, porous composite membrane, and mixture to form a porous moldable material | |
KR20170005148A | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |